First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

Core Insights - BridgeBio Pharma's Phase 3 clinical trial of acoramidis demonstrated a 59.1% risk reduction in all-cause mortality (ACM) or first cardiovascular hospitalization (CVH) in patients with hereditary transthyretin amyloidosis (ATTRv-CM) compared to placebo, supporting the hypothesis that stabilizing TTR may delay or prevent the disease [1][5] Group 1: Clinical Trials and Studies - The ACT-EARLY study is a randomized, double-blind, placebo-controlled trial enrolling approximately 600 asymptomatic carriers of a pathogenic TTR variant, aiming to evaluate the primary analysis of ATTRv disease diagnosis [1][3] - Acoramidis, a near-complete TTR stabilizer, is being tested in the ACT-EARLY study to determine if prophylactic treatment can delay or prevent the onset of variant ATTR [3][4] - The primary efficacy endpoint of the ACT-EARLY study is the time to development of ATTR-CM and/or ATTR-PN, with additional endpoints including safety, tolerability, and effects on cardiac imaging parameters [3] Group 2: Regulatory Approvals and Market Position - Acoramidis is approved as Attruby™ by the U.S. FDA and as BEYONTTRA by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and the UK Medicines and Healthcare Products Regulatory Agency, all indicating near-complete stabilization of TTR [1][6] - Current therapies for ATTR amyloidosis are only approved for treating diagnosed disease and do not provide prevention options for asymptomatic carriers, highlighting a significant unmet need in the market [4][6] Group 3: Industry Impact and Future Directions - The launch of the ACT-EARLY study reflects BridgeBio's commitment to advancing the genetic understanding of ATTR variants and improving patient care globally [2] - The study aims to establish a new prevention paradigm for asymptomatic carriers of genetic variants, potentially leading to earlier intervention and better clinical outcomes [2][4]